1. Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: an overview. Am Fam Physician 2006;74:125-130.
2. Schwartz JR, Messenger AG, Tosti A, Todd G, Hordinsky M, Hay RJ, Wang X, Zachariae C, Kerr KM, Henry JP, Rust RC, Robinson MK. A comprehensive pathophysiology of dandruff and seborrheic dermatitis: towards a more precise definition of scalp health. Acta Derm Venereol 2013;93:131-137.
3. Lee YW, Yim SM, Lim SH, Choe YB, Ahn KJ. Quantitative investigation on the distribution of Malassezia species on healthy human skin in Korea. Mycoses 2006;49:405-410.
4. Faergemann J, Johansson S, Back O, Scheynius A. An immunologic and cultural study of Pityrosporum folliculitis. J Am Acad Dermatol 1986;14:429-433.
5. Mayer-da-Silva A, Gollnick H, Detmar M, Gassmüller J, Parry A, Muller R, Orfanos CE. Effects of azelaic acid on sebaceous gland, sebum excretion rate and keratinization pattern in human skin: an in vivo and in vitro study. Acta Derm Venereol Suppl (Stockh) 1989;143:20-30.
6. Peyri J, Lleonart M. Grupo espanol del Estudio SEBDERM. Clinical and therapeutic profile and quality of life of patients with seborrheic dermatitis. Actas Dermosifiliogr 2007;98:476-482.
7. Nicolas V, Nefussi JR, Collin P, Forest N. Effects of acidic fibroblast growth factor and epidermal growth factor on subconfluent fetal rat calvaria cell cultures: DNA synthesis and alkaline phosphatase activity. Bone Miner 1990;8:145-156.
9. Shuster S. The aetiology of dandruff and the mode of action of therapeutic agents. Br J Dermatol 1984;111:235-242.
10. Danby FW, Maddin WS, Margesson LJ, Rosenthal D. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol 1993;29:1008-1012.
12. Mills KJ, Hu P, Henry J, Tamura M, Tiesman JP, Xu J. Dandruff/seborrhoeic dermatitis is characterized by an inflammatory genomic signature and possible immune dysfunction: transcriptional analysis of the condition and treatment effects of zinc pyrithione. Br J Dermatol 2012;166:Suppl 2. 33-40.
13. Warner RR, Schwartz JR, Boissy Y, Dawson TL Jr. Dandruff has an altered stratum corneum ultrastructure that is improved with zinc pyrithione shampoo. J Am Acad Dermatol 2001;45:897-903.
14. Nenoff P, Haustein UF, Brandt W. Antifungal activity of the essential oil of Melaleuca alternifolia (tea tree oil) against pathogenic fungi in vitro. Skin Pharmacol 1996;9:388-394.
15. Homeyer DC, Sanchez CJ, Mende K, Beckius ML, Murray CK, Wenke JC, Akers KS. In vitro activity of Melaleuca alternifolia (tea tree) oil on filamentous fungi and toxicity to human cells. Med Mycol 2015;53:285-294.
16. Pazyar N, Yaghoobi R, Bagherani N, Kazerouni A. A review of applications of tea tree oil in dermatology. Int J Dermatol 2013;52:784-790.
17. Satchell AC, Saurajen A, Bell C, Barnetson RS. Treatment of dandruff with 5% tea tree oil shampoo. J Am Acad Dermatol 2002;47:852-855.
18. Van Cutsem J, Van Gerven F, Cauwenbergh G, Odds F, Janssen PA. The antiinflammatory effects of ketoconazole: a comparative study with hydrocortisone acetate in a model using living and killed Staphylococcus aureus on the skin of guinea-pigs. J Am Acad Dermatol 1991;25((2 Pt 1):257-261.
20. Gupta AK, Nicol K, Batra R. Role of antifungal agents in the treatment of seborrheic dermatitis. Am J Clin Dermatol 2004;5:417-422.
21. Lassus A, Nolting KS, Savopoulos C. Comparison of ciclopirox olamine 1% cream with ciclopirox 1%-hydrocortisone acetate 1% cream in the treatment of inflamed superficial mycoses. Clin Ther 1988;10:594-599.
22. Altmeyer P, Hoffmann K. Loprox Shampoo Dosing Concentration Study Group. Efficacy of different concentrations of ciclopirox shampoo for the treatment of seborrheic dermatitis of the scalp: results of a randomized, double-blind, vehicle-controlled trial. Int J Dermatol 2004;43:Suppl 1. 9-12.
23. Lee JH, Lee HS, Eun HC, Cho KH. Successful treatment of dandruff with 1.5% ciclopirox olamine shampoo in Korea. J Dermatolog Treat 2003;14:212-215.
24. Poulin Y, Papp K, Bissonnette R, Guenther L, Tan J, Lynde C, Kerrouche N, Villemagne H. CalePso Study Team.. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of scalp psoriasis. Cutis 2010;85:43-50.
25. Reygagne P, Poncet M, Sidou F, Soto P. Clobetasol propionate shampoo 0.05% in the treatment of seborrheic dermatitis of the scalp: results of a pilot study. Cutis 2007;79:397-403.
26. Ortonne JP, Nikkels AF, Reich K, Ponce Olivera RM, Lee JH, Kerrouche N, Sidou F, Faergemann J. Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0·05% combined with ketoconazole shampoo 2%: a randomized, controlled study. Br J Dermatol 2011;165:171-176.
28. Squire RA, Goode K. A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis. J Dermatolog Treat 2002;13:51-60.
29. Katsambas A, Antoniou C, Frangouli E, Avgerinou G, Michailidis D, Stratigos J. A double-blind trial of treatment of seborrhoeic dermatitis with 2% ketoconazole cream compared with 1% hydrocortisone cream. Br J Dermatol 1989;121:353-357.
30. Elewski B, Ling MR, Phillips TJ. Efficacy and safety of a new once-daily topical ketoconazole 2% gel in the treatment of seborrheic dermatitis: a phase III trial. J Drugs Dermatol 2006;5:646-650.
31. Dupuy P, Maurette C, Amoric JC, Chosidow O. Study Investigator Group. Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclopiroxolamine 1% cream in facial seborrhoeic dermatitis. Br J Dermatol 2001;144:1033-1037.
32. Goldust M, Ranjkesh MR, Amirinia M, Golforoushan F, Rezaee E, Rezazadeh Saatlou MA. Sertaconazole 2% cream versus hydrocortisone 1% cream in the treatment of seborrheic dermatitis. J Dermatolog Treat 2013;02. 24. [Epub]. 10.3109/09546634.2013.782384.
34. Berger TG, Duvic M, Van Voorhees AS, VanBeek MJ, Frieden IJ. American Academy of Dermatology Association Task Force. The use of topical calcineurin inhibitors in dermatology: safety concerns: report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006;54:818-823.
35. Kastarinen H, Okokon EO, Verbeek JH. Topical anti-inflammatory agents for seborrheic dermatitis of the face or scalp: summary of a Cochrane Review. JAMA Dermatol 2015;151:221-222.
37. Schlesinger T, Rowland Powell C. Efficacy and safety of a low molecular weight hyaluronic Acid topical gel in the treatment of facial seborrheic dermatitis final report. J Clin Aesthet Dermatol 2014;7:15-18.
38. Fabbrocini G, Cantelli M, Monfrecola G. Topical nicotinamide for seborrheic dermatitis: an open randomized study. J Dermatolog Treat 2014;25:241-245.
39. Scaparro E, Quadri G, Virno G, Orifici C, Milani M. Evalua-tion of the efficacy and tolerability of oral terbinafine (Daskil) in patients with seborrhoeic dermatitis: a multicentre, ran-domized, investigator-blinded, placebo-controlled trial. Br J Dermatol 2001;144:854-857.
40. Geissler SE, Michelsen S, Plewig G. Very low dose isotretinoin is effective in controlling seborrhea. J Dtsch Dermatol Ges 2003;1:952-958.